Oct 20, 2026 04:01PM
Oct 20, 2026 04:01PM
Aug 11, 2026 04:01PM
Jul 31, 2026 06:46AM
Jul 23, 2026 08:00AM
Jul 23, 2026 08:00AM
May 12, 2026 04:01PM Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Apr 7, 2026 12:33PM
Apr 7, 2026 08:15AM
Apr 7, 2026 08:00AM
Apr 7, 2026 08:00AM
Mar 26, 2026 04:01PM
Jan 21, 2026 06:10AM
Dec 29, 2025 11:25AM Jefferies on Inhibikase Therapeutics Inc (IKT): 'the stock at $200-250M cap is inexpensive'
Dec 26, 2025 06:41AM
Dec 11, 2025 08:04AM
Nov 20, 2025 04:01PM
Nov 20, 2025 04:01PM
Mar 31, 2025 06:45AM
Nov 14, 2024 08:37AM
Oct 21, 2024 09:05AM Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
Aug 14, 2024 04:25PM
Jun 17, 2024 08:05AM
Jun 5, 2024 08:05AM
May 20, 2024 08:01AM
May 20, 2024 08:01AM
May 15, 2024 08:00PM
May 15, 2024 08:45AM Inhibikase Therapeutics (IKT) Requests Withdrawal of S-1 Registration Statement
May 15, 2024 08:45AM
May 9, 2024 08:00AM
Apr 18, 2024 04:30PM
Apr 18, 2024 04:30PM
Apr 3, 2024 08:05AM
Apr 3, 2024 08:05AM
Mar 27, 2024 04:15PM Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Feb 28, 2024 04:06PM
Feb 28, 2024 04:05PM
Feb 7, 2024 07:55AM
Feb 7, 2024 07:55AM
Dec 19, 2023 08:31AM
Dec 19, 2023 08:30AM
Dec 4, 2023 08:35AM Inhibikase Therapeutics (IKT) Granted Pre-NDA Meeting with the FDA for IkT-001Pro
Dec 4, 2023 08:35AM
Nov 14, 2023 04:30PM
Oct 16, 2023 07:07AM
Oct 16, 2023 07:00AM
Oct 4, 2023 08:31AM
Oct 4, 2023 08:30AM
Aug 17, 2023 08:32AM Inhibikase Therapeutics (IKT) Completes 501 Bioequivalence Study of IkT-001Pro
Aug 17, 2023 08:30AM

335,221 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All